Lithuania At 2022 Bio International Convention – Europe’s Fastest Growing Life Science Cluster Seeks Closer Us Links
Lithuanian life science innovation will again be on display at the 2022 BIO International convention in San Diego. Innovation Agency Lithuania will showcase 8 leading Lithuanian biotech stars on the Lithuanian pavilion demonstrating why Lithuania is one of Europe’s fastest-growing life science hubs. All are looking to build stronger links with the US which is already the country’s biggest market accounting for 28% of its life science exports in 2021.
Life sciences have strong roots in the Baltic nation with the first enzyme factory opening over 50 years ago. Sustained double-digit growth over the last decade has encouraged the country to aim for life sciences reaching 5% of GDP by 2030. Already the hub centered mainly around Vilnius has more than 570 companies covering core life science products and services.
Key to achieving this is not only great ongoing research and government support but the deep and diverse pool of talent – Lithuania comes in second in the EU with 25% of students choosing STEM academic disciplines, out of 56% of the population with higher education. Furthermore, according to Eurostat, 58% of researchers in Lithuania are women.
Therefore BIO 2022’s “LIMITLESS” theme perfectly matches the opportunities for collaboration the exciting companies on the Innovation Agency Lithuania Pavilion will offer. Visitors will find a range of experts on the latest CRISPR genetic scissors technology, AI-Driven Protein design, drugs targeting cold tumors, pan-European clinical trials, and market access. They will also hear why leading companies such as Biogen, Cureline, Teva, Hollister, or Thermo Fisher have chosen to establish operations in Lithuania.
“Life sciences are a key priority for Lithuania and the 2022 BIO International Convention offers us the ideal platform to showcase our leading companies. We have a strong tradition in molecular biology and immunology demonstrated by companies such as Biomatter Designs, Genie Biotech, Felicitex, and CasZyme, while CRO and pharma service providers Insuvia, Biomapas and Cureline Baltic build on Lithuania’s reputation for excellence in clinical trials. We are also looking to build links with leading US and other global clusters”, says Andrius Sliuzas, Account Manager for Life Sciences Baltics projects at Innovation Agency Lithuania.
The companies attending are:
- Insuvia – pharmacovigilance services
- Biomapas – clinical trials and drug registration
- CasZyme – CRISPR gene editing tools
- Biomatter Designs – AI-driven protein design
- Cureline Baltic – precision medicine CRO
- Genie Biotech – bioconjugation tools and services
- Felicitex Therapeutics – targeting quiescent cancer cells
Lithuania rebounded to its former highest place in the world competitiveness index published by the Swiss Institute of International Management (IMD). In 2022, it ranks 29th among 63 countries.
Lithuania is a perfect place for women to join tech industries as the country is one of the fastest-growing centres of life sciences in Europe and has a vibrant ICT, financial technologies, video game, and laser sectors. The start-up community, which has already exceeded one thousand companies, attracts talents from all over the world to innovate and think about solutions that can contribute to a global change for the better in many spheres, ranging from gene editing to solving circular economy challenges.